Answers are grounded in this paper and cite their sources.
Hypertrophic cardiomyopathy in children is a heterogeneous disease requiring individualized management, early consideration for heart transplantation in symptomatic infants, and careful screening to prevent sudden death in asymptomatic athletes.
Hypertrophic cardiomyopathy is a congenital disease that may be manifested in infancy, childhood, adolescence, or young adulthood. It is heterogeneous both genotypically and phenotypically, and as such, it requires an individualized approach to medical management. The symptomatic patient can have progression of symptoms but can be treated with appropriate medical or surgical therapy. The symptomatic infant usually has a grave prognosis and should be given early consideration for heart transplantation. The future holds promise because genotyping may recognize pedigrees with more "malignant" courses that can be treated more aggressively to prevent sudden death. The greatest challenge lies with the primary care physician who must take careful measures to identify those asymptomatic patients who may be at risk for sudden death during athletic activities.
No takes yet. Share an insight, caveat, or question.
Randall M. Bryant (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: